BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu D, Qiu T, Zhang Q, Kang H, Yuan S, Zhu L, Zhu R. Systematic toxicity mechanism analysis of proton pump inhibitors: an in silico study. Chem Res Toxicol 2015;28:419-30. [PMID: 25626140 DOI: 10.1021/tx5003782] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Chen Y, Zeng B, Shi P, Xiao H, Chen S. Comparative Analysis of the Liver and Spleen Transcriptomes between Holstein and Yunnan Humped Cattle. Animals (Basel) 2019;9:E527. [PMID: 31387199 DOI: 10.3390/ani9080527] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
2 Zeng Y, Liu L, Zhu L, Zhan X, Peng F, Feng X, Zhou Q, Zhang Y, Wang Z, Liang J, Li J, Wen Y. Proton pump inhibitor usage is associated with higher all-cause mortality and CV events in peritoneal dialysis patients. Ren Fail 2022;44:407-14. [PMID: 35236240 DOI: 10.1080/0886022X.2022.2043903] [Reference Citation Analysis]
3 Corsonello A, Lattanzio F. Cardiovascular and non-cardiovascular concerns with proton pump inhibitors: Are they safe? Trends in Cardiovascular Medicine 2019;29:353-60. [DOI: 10.1016/j.tcm.2018.10.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
4 Belhadj Z, He B, Fu J, Zhang H, Wang X, Dai W, Zhang Q. Regulating Interactions Between Targeted Nanocarriers and Mononuclear Phagocyte System via an Esomeprazole-Based Preconditioning Strategy. Int J Nanomedicine 2020;15:6385-99. [PMID: 32922007 DOI: 10.2147/IJN.S258054] [Reference Citation Analysis]
5 Li X, Kang H, Liu W, Singhal S, Jiao N, Wang Y, Zhu L, Zhu R. In silico design of novel proton-pump inhibitors with reduced adverse effects. Front Med 2019;13:277-84. [PMID: 29845582 DOI: 10.1007/s11684-018-0630-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Rizvi F, Khan M, Jabeen A, Siddiqui H, Choudhary MI. Studies on Isoniazid Derivatives through a Medicinal Chemistry Approach for the Identification of New Inhibitors of Urease and Inflammatory Markers. Sci Rep 2019;9:6738. [PMID: 31043636 DOI: 10.1038/s41598-019-43082-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
7 Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open. 2017;7:e015735. [PMID: 28676480 DOI: 10.1136/bmjopen-2016-015735] [Cited by in Crossref: 134] [Cited by in F6Publishing: 117] [Article Influence: 26.8] [Reference Citation Analysis]
8 Xu Q, Jia X, Wu Q, Shi L, Ma Z, Ba N, Zhao H, Xia X, Zhang Z. Esomeprazole affects the proliferation, metastasis, apoptosis and chemosensitivity of gastric cancer cells by regulating lncRNA/circRNA-miRNA-mRNA ceRNA networks. Oncol Lett 2020;20:329. [PMID: 33101498 DOI: 10.3892/ol.2020.12193] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury. Kidney Int. 2017;91:1482-1494. [PMID: 28237709 DOI: 10.1016/j.kint.2016.12.021] [Cited by in Crossref: 86] [Cited by in F6Publishing: 70] [Article Influence: 17.2] [Reference Citation Analysis]
10 Song HJ, Jiang X, Henry L, Nguyen MH, Park H. Proton pump inhibitors and risk of liver cancer and mortality in patients with chronic liver disease: a systematic review and meta-analysis. Eur J Clin Pharmacol 2020;76:851-66. [PMID: 32172363 DOI: 10.1007/s00228-020-02854-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
11 Mills JA, Liu F, Jarrett TR, Fletcher NL, Thurecht KJ. Nanoparticle based medicines: approaches for evading and manipulating the mononuclear phagocyte system and potential for clinical translation. Biomater Sci 2022. [PMID: 35419582 DOI: 10.1039/d2bm00181k] [Reference Citation Analysis]
12 Gelfond D, Heltshe SL, Skalland M, Heubi JE, Kloster M, Leung DH, Ramsey BW, Borowitz D; BONUS Study Investigators. Pancreatic Enzyme Replacement Therapy Use in Infants With Cystic Fibrosis Diagnosed by Newborn Screening. J Pediatr Gastroenterol Nutr 2018;66:657-63. [PMID: 29176494 DOI: 10.1097/MPG.0000000000001829] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]